Veröffentlichungen

Publikationen

Wissenschaftliche Veröffentlichungen

Hier finden Sie wissenschaftliche Veröffentlichungen des BiKeR-Projektes in umgekehrt chronologischer Reihenfolge:

Incident psoriasis under treatment with tumor necrosis factor-α inhibitors in juvenile idiopathic arthritis patients-analysis of the BiKeR registry.

Zimmer A, Klein A, Kuemmerle-Deschner JB, Dressler F, Onken N, Brueck N, Fasshauer M, Hospach T, Hufnagel M, Foell D, Horneff G. Rheumatol Int. 2023 Jun 9. doi: 10.1007/s00296-023-05352-z. Online ahead of print.PMID: 37291093

Mehr erfahren

Biologics with or without methotrexate in treatment of polyarticular juvenile idiopathic arthritis: effectiveness, safety and drug survival.

Thiele F, Klein A, Klotsche J, Windschall D, Dressler F, Kuemmerle-Deschner J, Minden K, Foeldvari I, Foell D, Mrusek S, Oommen PT, Horneff G.Rheumatology (Oxford). 2023 Jun 1;62(6):2230-2238. doi: 10.1093/rheumatology/keac587.PMID: 36222562

Mehr erfahren

Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.

Broekaert IJ, Klein A, Windschall D, Rogalski B, Weller-Heinemann F, Oommen P, Küster M, Foeldvari I, Minden K, Hospach A, Hufnagel M, Berger T, Geikowski T, Quietzsch J, Horneff G.J Pediatr Gastroenterol Nutr. 2023 Feb 1;76(2):174-182. doi: 10.1097/MPG.0000000000003656. Epub 2022 Nov 18.PMID: 36399775

Mehr erfahren

Oral or Parenteral Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis.

Bakry R, Klein MA, Horneff G.Eur J Rheumatol. 2022 Oct;9(4):197-205. doi: 10.5152/eurjrheum.2022.21090.PMID: 35943454

Mehr erfahren

Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries.

Kearsley-Fleet L, Klotsche J, van Straalen JW, Costello W, D'Angelo G, Giancane G, Horneff G, Klein A, Láday M, Lunt M, de Roock S, Ruperto N, Schoemaker C, Vijatov-Djuric G, Vojinovic J, Vougiouka O, Wulffraat NM; UK JIA Biologics Registers Investigators Group; Paediatric Rheumatology International Trials Organisation (PRINTO); Hyrich KL, Minden K, Swart JF.Rheumatology (Oxford). 2022 May 30;61(6):2524-2534. doi: 10.1093/rheumatology/keab641.PMID: 34613385

Mehr erfahren

Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study.

Thiele F, Klein A, Hospach A, Windschall D, Mrusek S, Ruehlmann JM, Horneff G.ACR Open Rheumatol. 2021 Nov;3(11):779-787. doi: 10.1002/acr2.11325. Epub 2021 Aug 27.PMID: 34449981

Mehr erfahren

Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis.

Klotsche J, Klein A, Niewerth M, Hoff P, Windschall D, Foeldvari I, Haas JP, Horneff G, Minden K.Arthritis Res Ther. 2021 Apr 16;23(1):118. doi: 10.1186/s13075-021-02492-0.PMID: 33863349

Mehr erfahren

Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry.

Thiele F, Klein A, Windschall D, Hospach A, Foeldvari I, Minden K, Weller-Heinemann F, Horneff G.Rheumatol Int. 2021 Apr;41(4):751-762. doi: 10.1007/s00296-020-04774-3. Epub 2021 Feb 16.PMID: 33590331

Mehr erfahren

Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry.

Raab A, Kallinich T, Huscher D, Foeldvari I, Weller-Heinemann F, Dressler F, Kuemmerle-Deschner JB, Klein A, Horneff G.Pediatr Rheumatol Online J. 2021 Mar 22;19(1):41. doi: 10.1186/s12969-021-00522-4.PMID: 33752685

Mehr erfahren

Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry.

Atemnkeng Ntam V, Klein A, Horneff G.Expert Opin Drug Saf. 2021 Jan;20(1):93-100. doi: 10.1080/14740338.2021.1843631. Epub 2020 Nov 18.PMID: 33148061

Mehr erfahren

Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry.

Armaroli G, Klein A, Ganser G, Ruehlmann MJ, Dressler F, Hospach A, Minden K, Trauzeddel R, Foeldvari I, Kuemmerle-Deschner J, Weller-Heinemann F, Urban A, Horneff G.Arthritis Res Ther. 2020 Oct 29;22(1):258. doi: 10.1186/s13075-020-02326-5.PMID: 33121528

Mehr erfahren

Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.

Klein A, Klotsche J, Hügle B, Minden K, Hospach A, Weller-Heinemann F, Schwarz T, Dressler F, Trauzeddel R, Hufnagel M, Foeldvari I, Borte M, Kuemmerle-Deschner J, Brunner J, Oommen PT, Föll D, Tenbrock K, Urban A, Horneff G.Rheumatology (Oxford). 2020 Sep 1;59(9):2287-2298. doi: 10.1093/rheumatology/kez577.PMID: 31846042

Mehr erfahren

Biologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Long-Term Safety Data from the German BIKER Registry.

Klein A, Becker I, Minden K, Hospach A, Schwarz T, Foeldvari I, Huegle B, Borte M, Weller-Heinemann F, Dressler F, Kuemmerle-Deschner J, Oommen PT, Foell D, Trauzeddel R, Rietschel C, Horneff G.ACR Open Rheumatol. 2020 Jan;2(1):37-47. doi: 10.1002/acr2.11091. Epub 2019 Nov 24.PMID: 31943968

Mehr erfahren

Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.

Klein A, Becker I, Minden K, Foeldvari I, Haas JP, Horneff G.Scand J Rheumatol. 2019 Mar;48(2):95-104. doi: 10.1080/03009742.2018.1488182. Epub 2018 Nov 9.PMID: 30411654

Mehr erfahren

Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.

Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva Е, Panaviene V, Bader-Meunier B, Anton J, Nielsen S, De Benedetti F, Kamphuis S, Staņēviča V, Tracahana M, Ailioaie LM, Tsitsami E, Klein A, Minden K, Foeldvari I, Haas JP, Klotsche J, Horne AC, Consolaro A, Bovis F, Bagnasco F, Pistorio A, Martini A, Wulffraat N, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO), BiKeR and the board of the Swedish Registry.Arthritis Res Ther. 2018 Dec 27;20(1):285. doi: 10.1186/s13075-018-1780-z.PMID: 30587248

Mehr erfahren

Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.

Klotsche J, Minden K, Niewerth M, Horneff G.Ann Rheum Dis. 2018 Jul;77(7):996-1002. doi: 10.1136/annrheumdis-2017-211968. Epub 2018 Feb 16.PMID: 29453217

Mehr erfahren

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.

Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, Trauzeddel R, Ganser G, Weller-Heinemann F, Haas JP.Arthritis Res Ther. 2017 Nov 22;19(1):256. doi: 10.1186/s13075-017-1462-2.PMID: 29166924

Mehr erfahren

A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities.

Beukelman T, Anink J, Berntson L, Duffy C, Ellis JA, Glerup M, Guzman J, Horneff G, Kearsley-Fleet L, Klein A, Klotsche J, Magnusson B, Minden K, Munro JE, Niewerth M, Nordal E, Ruperto N, Santos MJ, Schanberg LE, Thomson W, van Suijlekom-Smit L, Wulffraat N, Hyrich K.Pediatr Rheumatol Online J. 2017 Apr 19;15(1):31. doi: 10.1186/s12969-017-0161-5.PMID: 28424093

Mehr erfahren

Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.

Horneff G, Klein A, Klotsche J, Minden K, Huppertz HI, Weller-Heinemann F, Kuemmerle-Deschner J, Haas JP, Hospach A.Arthritis Res Ther. 2016 Nov 24;18(1):272. doi: 10.1186/s13075-016-1170-3.PMID: 27881144

Mehr erfahren

Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis

Windschall D, Horneff G.
Clin Rheumatol. 2016 Oct 5. [Epub ahead of print]

Mehr erfahren

Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry

Horneff G, Klein A, Oommen PT, Hospach A, Foeldvari I, Feddersen I, Minden K. Clin Exp Rheumatol. 2016 Sep 8. [Epub ahead of print]

Mehr erfahren

Risk of serious infection in juvenile idiopathic arthritis patients associated with TNF-inhibitors and disease activity in the German BIKER registry

Becker I, Horneff G.
Arthritis Care Res (Hoboken). 2016 Jul 7. doi: 10.1002/acr.22961. [Epub ahead of print]

Mehr erfahren

Biologic-associated infections in pediatric rheumatology.

Horneff G.
Curr Rheumatol Rep. 2015 Nov;17(11):66. doi: 10.1007/s11926-015-0542-z. Review.

Mehr erfahren

Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics.

Barthel D, Ganser G, Kuester RM, Onken N, Minden K, Girschick HJ, Hospach A, Horneff G.
J Rheumatol. 2015 Nov;42(11):2160-5. doi: 10.3899/jrheum.140472.

Mehr erfahren

Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.

Foeldvari I, Becker I, Horneff G.
Arthritis Care Res (Hoboken). 2015 Nov;67(11):1529-35. doi: 10.1002/acr.22613.

Mehr erfahren

Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).

Klotsche J, Niewerth M, Haas JP, Huppertz HI, Zink A, Horneff G, Minden K.
Ann Rheum Dis. 2015 Apr 29. pii: annrheumdis-2014-206747. doi: 10.1136/annrheumdis-annrheumdis-2014-206747

Mehr erfahren

Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years.

Windschall D, Müller T, Becker I, Horneff G.
Rheumatol Int. 2015 Apr;35(4):613-8. doi: 10.1007/s00296-014-3125-9. Epub 2014 Sep 11.

Mehr erfahren

Incidence of herpes zoster infections in juvenile idiopathic arthritis patients.

Nimmrich S, Horneff G.
Rheumatol Int. 2015 Mar;35(3):465-70. doi: 10.1007/s00296-014-3197-6. Epub 2015 Jan 13

Mehr erfahren

[Current news from the BIKER register]

Horneff G, Minden K, Foeldvari I, Onken N, Windschall D, Hospach A, Ganser G, Klotsche J, Becker I; BIKER-Register Studiengruppe.
Z Rheumatol. 2014 Dec;73(10):897-906. doi: 10.1007/s00393-014-1397-9. German.

Mehr erfahren

Predictors of response to methotrexate in juvenile idiopathic arthritis.

Albarouni M, Becker I, Horneff G.
Pediatr Rheumatol Online J. 2014 Aug 13;12:35. doi: 10.1186/1546-0096-12-35. eCollection 2014.

Mehr erfahren

Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis.

Windschall D, Müller T, Becker I, Horneff G.
Clin Rheumatol. 2015 Jan;34(1):61-9. doi: 10.1007/s10067-014-2744-6. Epub 2014 Jul 18.

Mehr erfahren

[Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care]

Niewerth M, Minden K, Klotsche J, Horneff G.
Z Rheumatol. 2014 Aug;73(6):532-40. doi: 10.1007/s00393-014-1378-z. German.

Mehr erfahren

Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.

Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G.
Arthritis Rheumatol. 2014 Sep;66(9):2580-9. doi: 10.1002/art.38741.

Mehr erfahren

Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score

Horneff G, Becker I.
Rheumatology (Oxford). 2014 Jul;53(7):1229-34. doi: 10.1093/rheumatology/ket470. Epub 2014 Mar 4.

Mehr erfahren

Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis.

Geikowski T, Becker I, Horneff G; German BIKER Registry Collaborative Study Group.
Rheumatology (Oxford). 2014 Jul;53(7):1245-9. doi: 10.1093/rheumatology/ket490. Epub 2014 Mar 4.

Mehr erfahren

Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept

Klotsche J, Minden K, Thon A, Ganser G, Urban A, Horneff G.
Arthritis Care Res (Hoboken). 2014 Feb;66(2):253-62. doi: 10.1002/acr.22112

Mehr erfahren

Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry

Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G.
Arthritis Care Res (Hoboken). 2012 Sep;64(9):1349-56. doi: 10.1002/acr.21697

Mehr erfahren

Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept

van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, Armbrust W, Minden K, Prince FH, Kokke FT, Nieuwenhuis EE, Horneff G,WulffraatNM.
J Rheumatol. 2011 Jul;38(7):1441-6. Epub 2011 Apr 1.

Mehr erfahren

Report on malignancies in the German juvenile idiopathic arthritis registry

Horneff G, Foeldvari I,Minden K, Moebius D, Hospach T.
Rheumatology (Oxford). 2011 Jan;50(1):230-6.

Mehr erfahren

Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis

Papsdorf V, Horneff G.
Rheumatology (Oxford). 2011 Jan;50(1):214-21. Erratum in: Rheumatology (Oxford). 2011 Apr;50(4):814

Mehr erfahren

Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis.

Horneff G.
Z Rheumatol. 2010 Aug;69(6):516-26. Review. German.

Mehr erfahren

Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA's report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009.

Horneff G, Hospach T, Dannecker G, Föll D, Haas JP, Girschick HJ, Huppertz HI, Keitzer R, Laws HJ, Michels H, Minden K, Trauzeddel R.
Z Rheumatol. 2010 Aug;69(6):561-7. German.

Mehr erfahren

Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept

Halbig M, Horneff G.
Rheumatol Int. 2009 Dec;30(2):229-38

Mehr erfahren

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry

Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H; German and Austrian Paediatric Rheumatology Collaborative Study Group.
Ann Rheum Dis. 2009 Apr;68(4):519-25. Epub 2008 Apr 15

Mehr erfahren

Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years

Tzaribachev N, Kuemmerle-Deschner J, Eichner M, Horneff G.
Rheumatol Int. 2008 Aug;28(10):1031-4. Epub 2008 Mar 28

Mehr erfahren

Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis

Kuemmerle-Deschner JB, Horneff G.
Rheumatol Int. 2007 Dec;28(2):153-6. Epub 2007 Jul 20.

Mehr erfahren

Etanercept and uveitis in patients with juvenile idiopathic arthritis

Schmeling H, Horneff G.
Rheumatology (Oxford). 2005 Aug;44(8):1008-11. Epub 2005 Apr 26

Mehr erfahren

Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years.

Tzaribachev N, Kuemmerle-Deschner J, Eichner M, Horneff G.
Rheumatol Int. 2008 Aug;28(10):1031-4. Epub 2008 Mar 28

Mehr erfahren

Etanercept and uveitis in patients with juvenile idiopathic arthritis

Schmeling H, Horneff G.
Rheumatology (Oxford). 2005 Aug;44(8):1008-11. Epub 2005 Apr 26

Mehr erfahren

The German etanercept registry for treatment of juvenile idiopathic arthritis

Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, Küster RM, Michels H, Moebius D, Rogalski B, Thon A; Paediatric Rheumatology Collaborative Group.
Ann Rheum Dis. 2004 Dec;63(12):1638-44. Epub 2004 Apr 28. Review.

Mehr erfahren